With the increased use of next-generation sequencing, analyses of the genomic background of GBM have identified multiple putatively actionable mutations in driver genes, including in EGFR, CDK4, PDGFRA, CDKN2A/2B, BRAF, and PTEN (9). This evidence concerns the gene EGFR and glioblastoma.